Journal of Geriatric Psychiatry and Neurology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Free Access - Register Here

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karlawish, J. H. T.
Right arrow Articles by Casarett, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karlawish, J. H. T.
Right arrow Articles by Casarett, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Geriatric Psychiatry and Neurology, Vol. 14, No. 4, 222-228 (2001)
DOI: 10.1177/089198870101400407

Addressing the Ethical Challenges of Clinical Trials That Involve Patients with Dementia

Jason H. T. Karlawish, MD

David Casarett, MD

Research subjects face uncertainties, risks, burdens, and indignities, and research protocol requirements inhibit the physician's ability to make individualized treatment decisions. To address these problems, investigators and Institutional Review Boards (IRBs) should justify research risks using informed consent and the judgment that the risks of research are reasonable with respect to the potential benefits, if any, to subjects and to the expectation that the research will produce important knowledge. But clinical research in Alzheimer's disease (AD) presents inves tigators and IRBs with significant challenges to achieve these two requirements. Broadly, these challenges are the result of the impact of patients' cognitive impairment and the caregiving experience on decision making and the indeterminacy of defining clinically meaningful treatment benefits. In this article, we review the data that begin to answer whether and how patients' cognitive impairments and the caregiving experience impact on their decision making and what kinds of research results justify research risks. We will use these data to suggest changes to the design and conduct of clinical research in AD that can meet the challenge of justifying research risks. (J Geriatr Psychiatry Neurol 2001; 14:222-228).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Clin TrialsHome page
D. K Brandt, J. A Hind, J. Robbins, A. S Lindblad, G. Gensler, G. Gill, H. Baum, D. Lilienfeld, J. A Logemann, and Communication Sciences and Disorders Clinical Tria
Challenges in the design and conduct of a randomized study of two interventions for liquid aspiration
Clinical Trials, October 1, 2006; 3(5): 457 - 468.
[Abstract] [PDF]

Home page
 J. Med. EthicsHome page
A J Rosin and Y van Dijk
Subtle ethical dilemmas in geriatric management and clinical research
J. Med. Ethics, June 1, 2005; 31(6): 355 - 359.
[Abstract] [Full Text] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
N. R. Barbas and E. A. Wilde
Competency Issues in Dementia: Medical Decision Making, Driving, and Independent Living
J Geriatr Psychiatry Neurol, December 1, 2001; 14(4): 199 - 212.
[Abstract] [PDF]